Blog
RSS FeedPosted by Michael Wonder on 03 Nov 2016
Tesaro announces submission of niraparib new drug application for platinum-sensitive, recurrent ovarian cancer
1 November 2016 - Teasro today announced that it has completed the niraparib rolling new drug application submission to the U.S. ...
Posted by Michael Wonder on 03 Nov 2016
Health reform and the changing safety net in the United States
2 November 2016 - The authors describe the implications of the Affordable Care Act for safety-net health systems and how hospital-based ...
Posted by Michael Wonder on 02 Nov 2016
California’s Proposition 61: will direct democracy impact prescription-drug pricing?
1 November 2016 - Even in this unconventional election season, California politics has generated little national interest. ...
Posted by Michael Wonder on 02 Nov 2016
Costs keep women from taking drugs to prevent cancer’s return
1 November 2016 - Poverty and higher out-of-pocket drug costs may be the main reason that some women don’t stick ...
Posted by Michael Wonder on 02 Nov 2016
Generic drug backlog at the FDA: a dive into the confusing numbers
2 November 2016 - As the debate over skyrocketing drug prices continues, at least one solution has cropped up in ...
Posted by Michael Wonder on 02 Nov 2016
Give and take: US pharma & payers forge risk-sharing deals for new heart drugs
1 November 2016 - U.S. commercial payers and pharmaceutical companies have rarely engaged in outcomes-based risk-sharing arrangements, at least until ...
Posted by Michael Wonder on 02 Nov 2016
Sanders takes aim at insulin makers in latest price attack
1 November 2016 - Eli Lilly shares briefly drop after tweet by senator. ...
Posted by Michael Wonder on 02 Nov 2016
How health care hurts your paycheck
2 November 2016 - If there is a coherent theme to this year’s election, it is the growing economic frustration ...
Posted by Michael Wonder on 01 Nov 2016
ICER releases final report with pricing and coverage implications for treatment of advanced non-small cell lung cancer with TKI and PD-1 drugs
1 November 2016 - Prices for TKIs well aligned with added benefits for patients; prices for PD-1s too high. ...
Posted by Michael Wonder on 01 Nov 2016
Is high-deductible health insurance worth the risk?
31 October 2016 - As companies push workers to pay more for their medical care, millions of employees are facing ...
Posted by Michael Wonder on 01 Nov 2016
Novartis LEE011 (ribociclib) granted FDA priority review for first-line treatment of HR+/HER2- advanced breast cancer
1 November 2016 - A marketing authorization application for LEE011 plus letrozole has also been accepted for review by the ...
Posted by Michael Wonder on 31 Oct 2016
As health premiums jump, Obama wields an imperfect shield
30 October 2016 - Urging people to sign up for coverage under the Affordable Care Act, President Obama said last ...
Posted by Michael Wonder on 30 Oct 2016
Roche announces FDA approval for Ventana PD-L1 (SP142) assay to support immunotherapy treatment decisions in lung cancer
27 October 2016 - First FDA-approved test to support patient treatment decisions for Tecentriq (atezolizumab) in non-small-cell lung cancer. ...
Posted by Michael Wonder on 29 Oct 2016
FDA approves new device for prevention of recurrent strokes in certain patients
28 October 2016 - The U.S. FDA today approved the Amplatzer PFO Occluder device. ...
Posted by Michael Wonder on 29 Oct 2016
Sanofi and Regeneron receive complete response letter from FDA for sarilumab, an investigational treatment for rheumatoid arthritis
28 October 2016 - Sanofi and Regeneron Pharmaceuticals today announced the U.S. FDA issued a complete response letter regarding the ...